INDEX TO VOLUME 163

Author Index

Ablashi, D. V., 29
Abramson, I., 240
Abrignani, S., 219
Abzug, M. J., 1336
Adams, J., 966
Adams, R. B., 664
Adams, R., 483
Aeschlimann, A., 305
Agut, H., 1382
Ahmad, S., 1394
Ahmed-Ansari, A., 1223
Ahmed, F., 1235, 1243
Åkerlund, B., 710
Alberti, A., 400
Albornoz, M. A., 897
Alford, C. A., Jr., 17
Ali, M., 1243
Allen, S., 435, 918
Almeida, R. P., 853
Altman, N. L., 454
Altwegg, M., 890
Amin, R. D., 634
Amin, S., 876
Amodio, M., 197
Amstey, M. S., 679
Andersen, B. R., 920
Anderson, D. C., 441
Anderson, J., 710
Anderson, L. J., 687, 858
Anderson, P., 1073
Andersson, B., 1087
Andreu, 681
Andron, L., 414
Angelova, G., 873
Antoine, C., 1134
Antonelli, G., 882
Arciniega, J. L., 135
Arditi, M., 1164
Arimitsu, Y., 682
Armstrong, C., 1391
Armstrong, D., 202, 247
Arrowood, M. J., 1297
Arvin, A. M., 1016
Asensi, V., 574
Ashorn, P., 703
Ashton, F. E., 927
Asiri, S., 916
Aubin, J.-T., 1382
Auckenthaler, R., 1369
Aulitzky, W. E., 1344
Avila, M. M., 1167
Ayoub, E. M., 786
Azoulay-Dupuis, E., 319
Baba, M., 270
Badaró, F., 853
Badaró, R., 853
Baer, H. P., 916
Bagby, G. J., 83
Baginski, I., 996
Bajpai, V. K., 1394
Baker, C. J., 1141
Baker, J. C., 470
Baker-Zander, S. A., 825
Balachandran, N., 29
Balcarek, K. B., 460
Balk, A. H. M. M., 1385
Ballo, S., 679
Baron, L. S., 901
Baron, P., 247
Barral, A., 853
Barral-Netto, M., 853
Barriere, S. L., 201
Barthold, S. W., 419, 879
Bartok, A., 240
Basham, T., 869
Baudry, B., 507
Baumgartner, J. D., 762, 769
Beckmann, A. M., 393
Becx-Bleumink, M., 653
Bedos, J. P., 319
Belknap, E. B., 470
Benach, J. L., 1362
Bendtzen, K., 886
Bennetch, J. M., 12
Bennett, J. E., 849, 1154
Benton, J., 971
Benveniste, J., 1168
Berger, E. A., 703
Berglund, O., 710
Bermudez, L. E., 1286
Bernhisel-Broadbent, J., 908
Bernier, R. H., 1
Beyer, L., 336
Bienzle, U., 1161
Biggar, R. J., 57
Bille, J., 514, 1165
Bilous, A. M., 921
Binn, L. N., 7
Birkhead, G., 413
Bittker, S., 656
Blacklock, Z., 598
Bloesch, D., 89
Blum, M. R., 843
Blumberg, H. M., 1279
Bodey, G. P., 202
Bodsworth, N., 1138
Bonnez, W., 448
Bonventre, P. F., 524
Borkowsky, W., 1134
Bornstein, D., 413
Borschberg, U., 806
Boslego, J. W., 128
Boss, G. R., 240
Boswell, R. N., 971
Bouffard, P., 996
Bourgaux-Ramoisy, D., 1103
Boushira, M., 1305
Boutonnier, A., 530
Bouvet, E., 415
Boyle, M. D. P., 786
Bradley, C., 346
Brady, L. J., 786
Brady, W., 346
Brain, A. P. R., 549
Braun, D. G., 219
Breese Hall, C., 693
Breiman, R. F., 667
Breinig, M. K., 1001
Breman, J. G., 96
Brennan, P. J., 161
Brenner, D. J., 890
Brideau, R. J., 477
Briles, D. E., 812
Brinton, C. C., Jr., 128
Britigan, B. E., 819
Brodie, A., 441
Broeders, P. H. M., 640
Brollo, L., 400
Brouwer, M. L., 1385
Brown, A. E., 1145
Brown, B. A., 598
Brown, M., 293
Brown, Z. A., 226
Brüssow, H., 679
Brust, P., 325
Bryan, J. P., 1384
Bryan, L. E., 143
Buchbinder, S. P., 454, 959
Budge, E., 495
Buhles, W. C., 716
Burans, J. P., 257
Burchett, S. K., 226
Burman, L. Å, 1087
Burns, B. A., 1023
Burns, D. L., 135
Burroughs, M., 806
Busch, D. F., 716
Bush, L. M., 897
Buskell-Bales, Z., 57
Buti, M., 1351
Butzin, C. A., 971
Cabello, F., 656
Caddell, G. R., 17
Calandra, G., 735
Calandra, T., 769
Callahan, C., 483
Calmon, J., 1358
Calzavara, L., 699
Camargo, E. E., 908
Cameron, D. W., 233
Cammisuli, S., 89
Campbell, C. C., 1207
Campbell, J., 667
Campos, E. G., 895
Campos, M., 495
Cantoni, L., 1165
Caputo, G., 780
Cardellichio, C. B., 879
Cariani, E., 923, 1383
Carroll, D. J., 1279
Carter, A. O., 927
Carter, G. P., 660
Cartter, M. L., 282
Carvalho, E. M., 853
Casipit, C., 862
Castelnuovo, F., 923
Castro-Muñoz, E., 507
Causey, D. M., 1219
Caussy, D., 57
Ceri, H., 143
Ceroni, M., 488
Cerqueiro, M. C., 1167
Chai, Y. S., 819
Chaignat, C. L., 219
Chakraborty, J., 1235, 1243
Chaloupka, K., 386
Chambers, H. F., 1166
Chandwani, S., 1134
Chang, N., 1068
Chaowagul, W., 1145
Charreire, J., 1114
Chatterjee, D., 161
Chaussade, S., 1168
Chaves, M. F., 1161
Cheang, M., 233
Chein, N., 247
Chemin, I., 996
Chen, D.-S., 397
Chen, Y.-m. A., 47
Chesebro, B., 64
Chikaraishi, T., 925
Chirgwin, K., 757
Cho, S.-N., 161
Chou, S., 1229
Chowdhury, S., 1243
Christensson, B., 530
Chuard, C., 1369
Chun, C. S. Y., 786
Chung, R. C. Y., 128
Clark, E. G., 470
Clavijo,F., 219
Cleary, P. P., 109
Clemens, J. D., 1235, 1243
Clements, M. L., 740, 1023
Clerici, M., 971
Cloud, G. A., 460
Clover, R. D., 300
Coates, R. A., 699
Cohen, M. S., 819
Cohn, Z. A., 1195

The Journal of Infectious Diseases 1991;163:1409–1414
© 1991 by The University of Chicago. All rights reserved.
0022-1899/91/6306-0049$01.00

Cole, P. J., 549
Cole, S. L., 477
Coleman, P. J., 454
Coles, G. A., 837
Coligan, J. E., 41
Collier, A. C., 386
Collins-Lech, C., 187
Colthurst, D., 675
Connelly, B. L., 746
Conte, J. E., Jr., 169
Coombs, R. W., 226, 386
Cooper, D. A., 1138
Corey, L., 226, 386
Couch, R. B., 300
Coulaud, J. P., 415
Couturier, D., 1168
Cox, B., 1384
Cravioto, A., 1247
Crawford, S., 300
Croen, K. D., 23
Cross, A. S., 1040, 1055
Cruchaud, A., 219
Cryz, S. J., Jr., 901, 1040, 1055
Cummings, D. K., 386
Cunningham, A. L., 921
Currenti, M., 882
Daffe, M., 161
Dalgleish, A. G., 389
Daling, J. R., 393
Dance, D. A. B., 1145
Darip, D., 109
Das, S. R., 916
Davachi, F., 96
Davis, C. C., 799
Davis, R. M., 617
Davis, V., 930
Dawson, J. E., 564
Dayer, J. M., 219
Daza, R., 204
de Deckker, F. A., 1256
de Letona, J. M. L., 204
de Man, P., 331
de Repentigny, L., 1305
de Saint Martin, J., 53
de Souza, M. S., 879
De Clercq, E., 270
Dearlove, C. E., 336
DeArmond, B., 716
DeCarlo, E. S., 849
Deforest, A., 135
Dehlinger, M., 1219
del Vedovo, S., 1247
Denis, M., 919
Denizot, Y., 1164, 1168
Dennison, K. M., 1229
Dersch, M. W., 568
Des Jarlais, D. C., 923
Deslandes, S., 1103
Detruchis, P., 415
Dianzani, F., 882
Dickinson, C. M., 1157
Didier, E. S., 617
Didier, P. J., 617
Dierich, M. P., 1344
Dillon, H. C., 786
Dina, D., 219
Dinarello, C. A., 1177
DiNubile, M. J., 897
Dirren, H., 679
Dix, R. D., 720
Dodd, L. G., 1392
Doe, B., 219
Dohner, D. E., 858
Dolin, R., 448
Domurat, F. M., 71
Donaldson, K., 346
Donovan, B., 1138
Dorus, W., 1387
Dowton, D. N., 921
Dragovic, L., 23
Drew, W. L., 716, 1348, 1388
Dromer, F., 1114
Drucker, M., 193
Dukuly, Z. D., 376
Dummer, J. S., 1001
Dundas, D. F., 1150
DuPont, H. L., 946
Durand, D., 240
Dwyer, B., 904
Eberhard, M. L., 1157
Echeverria, P., 1062
Eckner, R. J., 966
Edmiston, C. E., Jr., 1148
Edwards, K. M., 740
Edwin, C., 524
Ehrnst, A., 710
Einhäupl, K. M., 311
Einzig, A. I., 197
Eisera, N., 926
El-Soofi, A., 916
Eliopoulos, G. M., 780
Ellerbeck, E., 735
Ellis, D., 929
Ellner, J. J., 1326
Engelhard, D., 628
Englund, G., 703
Engman, K., 710
Escamilla, J., 681
Eskola, J., 1029
Español, M. T., 1351
Essex, M., 47
Esteban, R., 1351
European Organization for Research and Treatment of Cancer, 951
Ewan, E. P., 927
Ewing, S. A., 564
Fabio, G., 926
Facklam, R. R., 644, 812, 1273
Fahrer, H., 305
Falcoff, E., 853
Falcoff, R., 853
Fanning, M., 699
Farber, J. M., 927
Farley, T. A., 282
Farmer, J. J., III, 660
Farmer, S. G., 1148
Farrell, T. P., 1108
Fattovich, G., 400
Feinberg, J., 1348
Feld, R., 202
Ferguson, M. A., 678
Fernández, F., 681
Fields, B. S., 667
Fierer, J., 574
Finberg, R. W., 156
Fiordalisi, G., 923, 1383
Fischer, G. W., 792
Fishbein, D. B., 564
Fitzgerald, N. A., 276
Fitzsimons, T. E., 631
Flaherty, J., 1393
Flanigan, T. P., 1391
Fleige, B., 866
Flynn, P. M., 843
Foley, K., 117
Folks, T. M., 41
Follansbee, S. E., 716
Forrest, B. D., 336
Fournier, J.-M., 530
Fraley, K., 109
Franciolli, M., 514, 1165
Francis, A., 699
Francis, D. P., 454
Frankel, G., 507
Fraser, V. J., 1378
Fredeking, T., 1055
Freeman, D. J., 728
Freeman, S. 414
Freij, L., 503
Freire, W. B., 679
Friedberg, D. N., 617
Friedland, G., 252
Friedman, C., 117
Fries, L. F., 1023
Frost, E. H., 1103
Fry, J., 507
Fukushi, H., 417
Fullen, G., 843
Fultz, P., 441
Fürer, E., 1040, 1055
Furukawa, S., 416
Gahagan, S., 483
Gajdusek, D. C., 488
Gakinya, M. N., 233
Galgiani, J. N., 671
Gallin, J. I., 849
Galloway, D. A., 393
Garcia-Monco, J. C., 1362
Garfield, M., 41
Gary, G. W., 282
Gaynes, R., 117
Gelber, R. H., 1374
Gelling, M., 757
Georgilis, K., 150
Gern, L., 305
Gershman, K., 735
Gibbs, C. J., Jr., 488
Gilden, D., 873
Gillespie, S. M., 282
Girón, J. A., 507
Giustina, G., 400
Givner, L. B., 1141
Glauser, M. P., 514, 762, 769, 1165
Glennon, M., 1256
Glezen, W. P., 300
Glorioso, J. C., 263
Gnann, J. W., Jr., 325
Goessens, W. H. F., 640
Goetz, M. B., 421
Gohr, C. M., 1148
Gold, J. W. M., 247
Gold, M. J., 1358
Goldberger, M. J., 1326
Goldstein, F. W., 780
Gomez, M., 495
Gonzales, L. A., 792
Gordon, S. M., 716
Gorman, P., 325
Grace, G. M., 671
Graham, G., 1016
Granfors, K., 409
Granger, A. M., 622
Grass, P., 1344
Grau, G. E., 96
Gray, B. M., 812
Grayston, J. T., 403
Greco, M. A., 1134
Greeff, M., 930
Green, B. M., 381
Greenberg, B. L., 495
Greenberger, P. A., 631
Greene, B. M., 376
Greene, K. D., 406
Gridley, G., 57
Griffin, D. E., 64
Griffith, B. P., 78
Grimminger, F., 362
Groves, E., 862
Grozinger, K., 966
Gryseels, B., 931
Guardia, J., 1351
Gullet, J., 716
Gulyas, M., 542
Gupta, R. S., 156
Gutierrez, M., 495
Habeshaw, J. A., 389
Hadler, J. L., 282
Hadler, S. C., 454
Hafner, R., 1219
Hahn, E. G., 866
Haikin, H., 628
Haines, D. M., 470
Halevy, R., 197
Hall, K., 971
Hallander, H. O., 1046
Halperin, S. A., 355
Halsey, N. A., 1023
Hammerschlag, M. R., 757
Hancock, V., 675
Hansen, E. J., 1267
Hantz, O., 996
Happ, C. M., 895
Hardy, D. J., 319

Haregewoin, A., 156
Hargrave, K. D., 966
Harris, J. R., 1235, 1243
Harris, L. J., 346
Harrison, S., 414
Hart, C. E., 959
Hartel, D., 252
Hartley, T. M., 252
Hashisaki, P. A., 1150
Hastings, J. G. M., 534
Hausknecht, E. C., 477
Hayes, C. G., 257
Hayward, A., 873
Healey, M. C., 1297
Hedberg, K., 96
Heesemann, J., 409
Heimberger, T., 413
Helfgott, D., 1390
Hendrix, C. W., 971
Hendry, R. M., 687
Heney, C., 930
Henrichsen, J., 1087
Herring, S. A., 1150
Herrmann, M., 1369
Hessol, N. A., 959
Hetherington, S. V., 843
Heumann, D., 762, 769
Hewlett, E. L., 135
Heynen, C., 1387
Hierholzer, J. C., 293
Higashi, Y., 682
Hightower, A. W., 96
Hill, H. R., 792
Hirai, K., 417
Hirsch, B. E., 197
Hirsch, V. M., 976
Hjelle, B., 435
Ho, M., 1001
Hoke, C. H., 989
Holdener, T., 869
Holmberg, S. D., 959
Holmes, K. V., 879
Holmgren, J., 503, 1235, 1243
Holodniy, M., 862
Holzer, T. J., 1387
Hook, E. W., III, 825
Horsburgh, C. R., 252
Howell, A. W., 644
Huber, C., 1344
Huda, S., 1235
Hudson, S. J., 720
Hughes, W. T., 202, 843
Huraux, J.-M., 1382
Hussain, M., 534
Hwang, S.-J., 1354
Innis, B. L., 989
International Antimicrobial Therapy Cooperative Group, 951
Ishihara, Y., 417
Isomura, S., 417
Israele, V., 1341
Israele, V., 1008
Issekutz, T. B., 355
Itami, N., 925
Jackson, H. C., 675
Jacobs, S., 921
Jacobson, D. L., 240
Jacobson, M. A., 1219, 1348
Jacot-Guillarmod, H., 762
Jafari, H. S., 1267
Jaffe, H. S., 908
Jakeman, K. J., 35
Janda, J. M., 890
Jansen, R. W., 7
Jardi, R., 1351
Jarolim, D. R., 1169
Jaurequi, E., 495
Jeannet, M., 219
Jeffery, P. K., 549
Jehuda-Cohen, T., 1223
Joab, I., 53
Jodal, U., 331
Johansson, M. E., 293
Johnson, C. C., 1358
Johnson, F. D., 135
Johnson, J. R., 325
Johnson, J. K., 699
Johnson, P. R., 976
Johnson, S. C., 128
Jones, T., 507
Jorgensen, J. H., 644
Judson, F. N., 454
Juto, P., 1087
Kaatz, G. W., 1080
Kakuk, T. J., 477
Kallings, I., 1087
Kalman, D., 201
Kameyama, S., 682
Kan, V. L., 1154
Kaneda, Y., 1170
Kaneshima, H., 625
Kano, R., 1170
Kao, T. C., 1384
Kaper, J. B., 507
Kapikian, A. Z., 483
Kaplan, E. L., 109
Kaplan, G., 1195
Karam, D., 415
Kasina, A., 355
Kass, E. H., 524
Katala, S., 752
Katzenstein, D. A., 862
Kawauichi-Kato, Y., 1170
Kay, B. A., 1235
Keath, E. J., 1378
Kebede, B., 653
Keefer, M. C., 448
Kela, E., 637
Keller, N., 122
Keller, U., 89
Kelsey, D. K., 792
Kennedy, C. A., 421
Kennedy, W., 843
Key, C., 435
Khabbaz, R. F., 41, 252
Khan, M. R., 1235, 1243
Khanna, B., 286
Kiehlbauch, J. A., 406, 1062
Kikuta, H., 925
Kilanowski, E., 1305
King, D., 1388
King, J. C., 740, 1023
Kirsh, M., 117
Kissel, V., 656
Kleinman, N., 1212
Klempner, M. S., 150
Klion, A. D., 1318
Klotz, S. A., 604
Knappe, W. A., 792
Kobayashi, S., 417
Koga, Y., 204
Kokka, R. P., 890
Kongchareon, S., 1145
Konisberger, H., 193
Konno, K., 270
Konrad, M., 862
Kopecko, D., 901
Koropchak, C. M., 1016
Koup, R. A., 966
Kovacs, J. A., 1121
Krah, D. L., 634, 735
Krämer, A., 866
Krasinski, K., 1134
Krause, P. H., 866
Kreiss, J. K., 233
Kremsner, P. G., 1161
Krepel, C. J., 1148
Kricek, F., 584
Krieger, J. N., 386
Kroes, A. C. M., 1385
Krueger, G. G., 728
Kumar, M. L., 876
Kurashige, T., 559
Kuratana, M., 1073
Kusne, S., 1001
Kuster, H., 806
LaBrooy, J. T., 336
Lagergård, T., 1087
Lahesmaa, R., 409
Lai, K.-H., 1354
Laine, E., 1029
Lairmore, M. D., 41, 252
Lal, R. B., 41
Lam, C., 584
Lammie, P. J., 1157
Lancaster, D. J., 843
Landry, M. L., 78
Lange, D. K., 7
Laorakpongse, T., 989
Larcher, K., 1344
Laughlin, C., 117
Lazzarin, A., 926
Lederman, H. M., 908
LeDuc, J. W., 7
Lee, L. A., 660
Lee, R. E., 1001
Lee, S.-D., 1354
Lee, T.-H., 47
Lefford, M. J., 653
Leibovici, L., 193, 928
Leinonen, M., 1029
Lemon, S. M., 7
Lentino, J. R., 1387
Leon-Barua, R., 495
Leport, C. 415
Lerner, R., 591
Letson, G. W., 483
Levin, E. M., 1212
Levin, M. J., 873, 1336
Levine, M. M., 901
Levine, S., 656
Levison, M. E., 1358
Levitz, S. M., 1108
Lew, D. P., 1369
Liao, S. H. T., 843
Lichodziejewska, M., 1033
Lidman, K., 710
Liehl, E., 584
Lifson, A. R., 959
Lin, J.-T., 397
Lindo, I., 495
Lindström, P., 591
Lipschik, G. Y., 1121
Lipsich, L., 346
Lo, K.-J., 1354
Lockwood, E., 1223
Long, C. E., 693
Lopardo, H. A., 780
Losonsky, G. A., 1, 901
Lu, R.-H., 1354
Lucet, J.-C., 1369
Lucey, D. R., 971
Lugoboni, F., 923
Lukeha.., S. A., 825
Lund, V., 549
Lundergan, L. L., 671
Lutz, F., 362
Lyamba, B., 96
Lyons, M. F., II, 325
Macarthy, P., 1384
MacFadden, D., 699
Mach, M., 1344
Mackenzie, R. K., 837
Magliato, S. A., 1336
Mahdi, A. A., 1394
Maher, L. A., 644
Mahon, A. C., 653
Majno, G., 937
Major, C. J., 699
Mäkelä, P. H., 637
Mäki-Ikola, O., 409
Malagelada, A., 1351
Malech, H. L., 849
Maloney, G., 346
Manclark, C. R., 135
Mandell, G. L., 202
Mantero, G., 923
Marchini, M., 926
Margolis, H. S., 286
Markowitz, L. E., 12
Markowitz, S. M., 780
Marosok, R., 117
Marra, C., 825
Marriott, M. S., 675
Martin, M. A., 703
Martindale, J., 1344

Martinez Ruiz, R., 204
Marton, A., 542
Marx, C. M., 1212
Maskell, D. J., 1366
Massougbodji, A., 1318
Mastro, T. D., 667
Masur, H., 1121
Mathai, A., 650
Mathijs, J.-M., 921
Mathisen, G. E., 421
Matson, C. C., 300
Matsubara, T., 416
Matsumoto, S., 925
Matthews, N., 1033
Matthews, T. R., 716
Mattingly, S. J., 143
Maupin, G. O., 895
Maurutia, D., 495
Mawle, A. C., 441, 959
Mayer, P., 584
Maziarz, R. T., 1108
McBean, A. M., 1
McCabe, R. E., 912
McCarthy, D. O., 71
McCaughtry, M., 735
McClure, H. M., 441, 1223
McCracken, G. H., Jr., 1267
McCune, J. M., 625
McCutchan, J. A., 240
McDougall, J. K., 393
McGowan, J., 625
McGuire, S. A., 971
McIlroy, M. A., 420
McIntosh, K., 687
McKeough, M. B., 728
McLaughlin, B. J., 699
McOlash, L., 1312
Mead, J. R., 1297
Meagher, S. G., 912
Mehalko, S. G., 716
Mehl, R., 931
Mellencamp, M. A., 102, 799
Mellors, J. W., 78
Melnick, D. A., 849
Mendaza, P., 204
Merigan, T. C., 862, 869
Merluzzi, V. J., 966
Mertens, D. A. E., 931
Mertz, G., 435
Mester, J. C., 263
Metcalf, J., 64
Meyers, J. D., 202
Meyohas, M.-C., 415
Mezzelani, P., 923
Michel-Harder, C., 1094
Michel, M. F., 640
Midthun, K., 735
Millán-Velasco, F., 507
Millichamp, N., 617
Milliken, J. S., 921
Mills, J., 1219
Mills, R., 435
Millson, M., 699
Miner, R. C., 716, 1348, 1388
Mishu, B., 918
Mittal, K., 1134
Miyake, T., 417
Mizuguchi, J., 682
Modlin, J. F., 1
Mogensen, S. C., 886
Mohanty, S. K., 622
Möllby, R., 1046, 1087
Moller, B., 886
Montagna, D., 219
Moore, L. S., 780
Moreillon, P., 514, 1165
Moret, P., 219
Morishita, T., 417
Morris, W., 12
Morse, D., 413
Moseley, S. L., 507, 773
Moss, B., 703
Motohashi, T., 416
Mowry-Hanley, J., 117
Moxon, E. R., 1366
Mullins, B. T., 912
Mummaw, N., 176
Munindhorn, W., 989
Munoz, R., 542
Muñoz, B., 376, 381, 752
Murphy, B. R., 740, 1023
Murphy, V. L., 386
Murray, B. E., 780, 1185
Murray, H. W., 622, 1390
Musher, D. M., 1201
Myers, A. R., 897
Myers, M. G., 746
Myerson, D., 393
Nagakura, N., 1170
Nainan, O. V., 286
Nalin, D. R., 634, 735
Namikawa, R., 625
Naparstek, E., 628
Narita, M., 204
Nash, D. R., 598
Nasnas, R., 780
National Cancer Institute of Canada–Clinical Trials, 951
Ndinya-Achola, J. O., 233
Need, J. T., 681
Neeser, J.-R., 1247
Neifer, S., 1161
Nelson, C. M., 109
Nelson, S., 83
Nelson, S. C., 897
Neogy, P. K., 1243
Ngugi, E. N., 233
Nguyen-Dinh, P., 96
NIAID Collaborative Antiviral Study Group, 17
Nichols, J. E., 71
Nicolas, J. C., 53
Niederwieser, D., 1344
Niemöller, U. M., 806
Nilsson, E., 591
Nohynek, H., 1029
Nolan, C. M., 1150
Norrby, R., 1087
Nurlign, A., 653
Nutman, T. B., 1128, 1318
O'Connor, S. P., 109
O'Donnell, J. J., 1348
O'Malley, P. M., 454
O'Shaughnessy, M. V., 699
Oberst, R. B., 257
Ogura, H., 559
Oh, M. K., 460
Okayama, A., 47
Olsen, K. D., 1267
Olsen, R., 325
Onorato, I. M., 1, 135
Opheim, K., 226
Or, R., 628
Orenstein, J. M., 617
Ortiz, M. A., 78
Orvell, C., 1167
Oshiro, L. S., 890
Östberg, L., 1344
Ostrove, J. M., 23
Ostrow, D. N., 454
Ottesen, E. A., 1128, 1318
Overbeek, B. P., 122
Owen, W. F., 716
Oxtoby, M. J., 1273
Pachucki, C. T., 1387
Pacqué, M., 376, 381
Palmblad, J., 591
Palmer, D., 918
Palmer, J., 1016
Palte, S., 843
Paluzzi, S. A., 897
Parenti, D. M., 1326, 1384
Park, C. S., 858
Parsonnet, J., 406
Pass, R. F., 460
Patarroyo, M., 591
Patterson, J. E., 780
Patterson, J. S., 470
Pavia, C. S., 656
Pearce, W., 325
Pedneault, L., 1305
Pedral-Sampaio, D., 853
Penley, K., 454
Perine, P. L., 1384
Perkis, V., 1023
Perricaudet, M., 53
Pesanti, E. L., 611
Peterkin, P. I., 927
Petersen, C. M., 886
Pfeiffer, B., 29
Pfeiffer, T., 929
Pfister, H.-W., 311
Picard, M., 371
Piepkorn, M. W., 728
Pierik, L. T., 687
Piesman, J., 895
Piot, P., 233
Pitarangsi, C., 1062
Pitlik, S. D., 193
Pizzo, P. A., 202, 579
Plessala, K. J., 83
Plikaytis, B. D., 667, 1273
Plummer, F. A., 233
Pneumococcal Surveillance Working Group, 1273
Pocidalo, J. J., 319
Pohle, H. D., 866
Pontisso, P., 400
Pou, S., 819
Povolotsky, P., 247
Powderly, W. G., 1378
Powell, J. D., 1223
Preac-Mursic, V., 311
Preblud, S. R., 12
Preheim, L. C., 102, 799
Primi, D., 923, 1383
Prober, C. G., 1016
Provost, P. J., 634
Provost, P., 735
Pruett, T. L., 664
Prüfer-Krämer, L., 866
Puoti, M., 923, 1383
Que, J. U., 1040, 1055
Quinn, B., 660
Quinn, D. L., 282
Raab-Traub, N., 1008
Rabin, L., 625
Radhakrishan, V. V., 650
Raff, H. V., 346, 792
Rahim, H., 679
Raios, K., 904
Rao, M. R., 1235, 1243
Raponi, G., 122
Rapoza, P., 752
Ravaggi, A., 1383
Rawlinson, W. D., 921
Read, R. C., 549
Read, S. E., 699
Realdi, G., 400
Rehg, J. E., 1293
Reichman, R. C., 448
Reid, R., 483
Rex, J. H., 849
Rice, L. B., 780
Richman, D. D., 240
Riecken, E. O., 866
Rikihisa, Y., 564
Riley, L. W., 507
Rimland, D., 1279
Rincon, J., 591
Ringertz, B., 591
Roberts, B., 252
Roberts, J. M., 1157
Roberts, M., 631
Roberts, N. J., Jr., 71, 448
Roberts, P. L., 325
Robertson, B. H., 286
Roblin, P. M., 757
Rodriguez-Frias, F., 1351
Rodriguez Diaz, J. C., 204
Roeder, T. L., 819
Rogers, M. D., 843
Roget, M., 1351
Rögler, G., 866
Rohner, P., 1369
Roilides, E., 579

Roman, F., 204
Ronald, A. R., 233
Rönnberg, P. R., 637
Rosen, G. M., 819
Rosenbaum, D., 843
Rosengren, S., 282
Ross, B. C., 904
Ross, S. O., 386
Rotbart, H. A., 1336
Rouse, B. T., 263
Rowe, N. H., 728
Rozenberg-Arska, M., 122
Rubeglio, E., 780
Rubin, M., 579
Ruble, C. A., 1080
Rudolph, D. L., 41
Ruiz, J., 1247
Ruol, A., 400
Rushton, D. I., 35
Rutman, A., 549
Ryan, J. L., 78
Ryding, U., 530
Sack, D. A., 503, 1235, 1243
Sack, R. B., 495
Sack, R., 483
Sadeler, B.-C., 1318
Sadoff, J. C., 128, 1040, 1055
Sáez-Llorens, X., 1267
Safar, J., 488
Sager, P., 625
Sahm, D., 1393
Sakazaki, R., 890
Salahuddin, S. Z., 29
Salata, R. A., 1391
Salazar-Lindo, E., 495
Salgo, M., 180
Salkind, A. R., 71
Salmon, D., 415
Salomón, H. E., 1167
Same, K., 413
Samorodin, R. K., 1023
Samra, Z., 193
Sande, M. A., 647
Santos, S. B., 853
Santosham, M., 483
Sarov, I., 628
Sarvas, H., 637
Sauvain, M.-J., 305
Sawyer, R. G., 664
Schaaf, D., 1387
Schable, C. A., 454
Schachter, J., 757
Schaefer, M. R., 1387
Schaffner, A., 1094
Schaffner, W., 918
Schermuck, S., 1161
Schielke, E., 311
Schimpff, S. C., 202
Schmal-Bauer, W., 640
Schmidt, E. V., 1212
Schnabel, K. C., 693
Schoenbaum, E. E., 252
Schoolnik, G. K., 507
Schulz, T. F., 1344
Schütze, E., 584
Schwan, T. G., 1391
Schwartz, D. H., 862
Schwartz, M., 1001
Scorza, R., 926
Scriba, M., 1344
Seeff, L., 57
Seeger, W., 362
Selby, R., 1001
Sell, K. W., 1223
Sengupta, S., 862
Seo, S. M., 1080
Shadduck, J. A., 617
Shaffer, N., 96
Shaked, O., 628
Shearer, G, 971
Shearman, D. J. C., 336
Sheehan, W. W., 1169
Shellam, G. R., 276
Shenep, J. L., 202, 843
Shepherd. F., 699
Sheppard, H. W., 959
Sherman, K. E. 414
Sherman, K. J., 393
Sheu, J.-C., 397
Shevchuk, Y. M., 203
Shibata, M., 204
Shigeta, S., 270
Shih, C.-C., 625
Shih, L.-N., 397
Shimada, T., 890
Shinonaga, S., 1170
Shioiri, S., 47
Shirley, P., 1008, 1341
Shuford, W., 346
Sidoti, J., 679
Sidwell, R. W., 1297
Sieber, F., 1312
Siegel, R. L., 441
Silcox, V. A., 598
Simmons, R. L., 1001
Simonsen, J. N., 233
Singh, B., 156
Singh, K. V., 780
Sixbey, J. W., 1008, 1341
Sjogren, M. H., 1384
Slavin, S., 628
Sliwa, K., 1161
Sloas, M., 1008
Smith, A. L., 879
Smith, H., 35
Smith, J., 598
Smith, O. M., 1312
Smith, R. S., 240
Smith, R. L., 604
Snitbhan, R., 989
Soeiro, R., 197
Sohn, Y. M., 460
Sohnle, P. G., 187
Sokol, P. A., 143
Sönnerborg, A., 710
Soong, S.-j., 17
Sörgel, F., 311
Spechko, P. L., 240
Spector, S. A, 240
Spengler, M. D., 664
Spika, J. S., 665, 1273
Spinas, G. A., 89
Spruance, S. L., 728
Staehelin, T., 219
Stalder, H., 219
Stamm, W. E., 325, 773
Stanberry, L. R., 746
Stanley, M., 959
Stapleton, A., 773
Stapleton, J. T., 7
Starzl, T. E., 1001
Steadman, R., 1033
Steel, C., 1128
Steele, L. C., 598
Steere, A. C., 150
Steimer, K. S., 219
Stein, D. S., 843
Steingrube, V. A., 598
Steinhoff, M. C., 740, 1023
Stenson, S. M., 617
Stern, A. C., 1344
Stewart, J. C. B., 728
Storch, G. A., 858
Storey, D. G., 143
Storey-Johnson, C., 1390
Storsaeter, J., 1046
Strannegård, O., 710
Straus, S. E., 23
Streilein, J. W., 720
Stricker, R. B., 441
Strockbine, N. A., 406
Stroop, W. G., 728
Stumacher, R. J., 897
Styrt, B., 176
Subbarao, E. K., 876
Sugar, A. M., 371
Sugarman, B., 176
Sullivan, J. L., 966
Sumter, G. 598
Suputtamongkol, Y., 1145
Sutter, R. W., 12
Svanborg, C., 331, 812
Svennerholm, A.-M., 1235, 1243
Swack, J. A., 524
Swanson, R. N., 319
Sweet, C., 35
Swenson, R. B., 441
Swenson, S., 435
Szczepanski, A., 1362
Taber, L. H., 300
Tachibana, H., 1170
Tachibana, N., 47
Tacket, C. O., 901
Tagger, A., 400
Takala, A. K., 637
Takashima, I., 682
Tanowitz, H. B., 180
Tartaglione, T., 226
Täuber, M. G., 647, 806
Tauxe, R. V., 660
Taylor, D. N., 901, 1062
Taylor, D. E., 1068
Taylor, H. R., 376, 381, 752
Taylor, J., 660
Tebas, P., 204
Tee, W., 1062
Tello, A., 1247
Tello, D., 1256
Teppo, A.-M., 1029
Terry, P., 1279
Thompson, J., 740
Thompson, J., 640
Thompson, J. J., 83
Thoms, M. L., 1
Thörner, Å., 293
Tilg, H., 1344
Ting, S. F., 1016
Tio, F. O., 617
Tirawatnapong, S., 29
Todd, H. C., 549
Todd, J. K., 678
Togashi, M., 925
Togashi, T. 204
Toivanen, A., 409
Toltzis, P., 1212
Tomasz, A., 542
Tomoda, T., 559
Torensma, R., 122
Tramont, E. C., 128
Traul, D. L., 1312
Trepo, C., 996
Triki, H., 53
Trollfors, B., 1087
Tsai, Y.-T., 1354
Tsou, C., 687, 858
Tsuda, K., 47
Tsuji, K., 416
Tsukamura, M., 598
Tuite, M. F., 675
Tuomanen, E., 806
Tureen, J. H., 647
Turrina, G., 923
Turriziani, O., 882
Udem, S. A., 180
Umezawa, Y., 416
Ushijima, H., 293
Vallée, E., 319
van Batenburg, M., 1385
van der Horst, C., 1219
van der Linden, S. M., 305
van Loon, F. P. L., 1235, 1243
Van Uitert, B. L., 897
Van Voris, L. P., 1391
Varughese, P. V., 927
Veilleux, S., 1103
Venturini, L., 923
Verhoef, J., 122
Vilde, J.-L., 415
Villafán, H., 1247
Villar, B. F., 1362
Villinger, F., 1223
Visberg, A., 495
Vogel, A. P., 976
Vogel, H. J., 143
Voorn, G. P., 640

Vossbrinck, C., 617
Wachsmuth, I. K., 406, 1279
Wade, J. C., 202
Wadell, G., 293
Waiyaki, P., 233
Wald, E. R., 678
Waldvogel, F. A., 1369
Walker, C. L., 631
Walker, L. C., 389
Walker, R. D., 470
Walker, T. S., 568
Wallace, M., 1016
Wallace, R. J., Jr., 598
Walls, M., 346
Walmrath, D., 362
Walsh, E. E., 71, 693
Walsh, T. J., 579
Walter, H., 362
Waltman, W. D., 812
Wang, A. M., 862
Wang, J.-T., 397
Wang, S.-p., 403
Wang, T.-H., 397
Ward, D. J., 1128
Ward, P., 346
Ward, W. W., 971
Waris, M., 464
Warren, H. S., 1256
Wassilak, S. G. F., 135
Watanabe, T., 416
Wathen, M. W., 477
Watson, N. E., 17
Watts, D. H., 226
Webster, A. D. B., 389
Webster, H. K., 1145
Wegmann, A., 1040
Wehrly, K., 64
Weigel, R., 866
Weinberg, M., 628
Weinstock, G., 780
Weiss, L. M., 180
Weissenbacher, M., 1167
Wendelboe, P., 886
Wendeler, M., 1358
Wenerstrom, L. G., 728
Werchau, H., 679
West, S. K., 752
White, A. T., 376
White, J. C., 176
White, N. J., 1145
White, N., 325
White, P. J., 534
White, W. E., 568
Whitley, R. J., 17
Whitmore, P. V., 1348
Wicher, K., 830
Wicher, V., 830
Wiessner, J. H., 187
Wilber, J. C., 959
Wilks, D., 389
Williams, A. E., 1366
Williams, J. D., 837, 1033
Williams, K., 524
Wilske, B., 311
Wilson, L. A., 83
Wilson, M. H., 1023
Wilson, R., 549
Winograd, D. F., 879
Winsber, M., 1016
Winters, R. A., 1390
Wintsch, J., 219
Wittner, M., 180
Wolf, W., 873
Wolff, E., 346
Wolff, M., 483
Wong, E. S., 780
Wood, S. W., 128
Woods, D. E., 143
Wright, P. F., 740
Wurtz, R., 1393
Wysenbeek, A. J., 928
Yabuta, K., 416
Yakshe, P. N., 57
Yan, W., 1068
Yee, R. W., 617
Yeginsoy, S., 1094
Yersinia enterocolitica Collaborative Study Group, 660
Yi, A., 495
Yogev, R., 1164
Yokota, T., 270
Yoshi, Z., 682
Young, L. S., 202, 1286
Yow, M. D., 202
Yunus, M., 1235
Zabek, J., 830
Zack, P. M., 976
Zarantonello, M., 926
Zaya, R. M., 477
Zea-Flores, G., 1128
Zell, E. R., 12
Zervos, M. J., 780
Zhang, Y., 598
Zhioua, E., 305
Zimmerli, W., 89
Zonaro, A., 923, 1383

Subject Index

Abscess, intraabdominal, effects of antigen exposure, 664
Acanthamoeba, meningitis, rifampicin for, 916
Acyclovir, for herpes simplex labialis, 728
Adenovirus type 31, genomic analysis, in immunocompromised patients, 293
Adherence
  C. albicans, mediated by fibronectin receptor, 604
  E. coli (EPEC), inhibition by secretory IgA, in breast milk, 1247
  H. influenzae, to respiratory mucosa, 549
Adhesion, neutrophil, impaired by ethanol, 591
Aeromonas, genetic and biochemical characterization, 890
AIDS
  ganciclovir-resistant CMV in, foscarnet for, 1348
  and *M. avium* infection, 1326
  patients, quantification of HIV from blood cells, 64
  PCP in, hydroxynapthoquinone for, 843
  Salmonella bacteremia in, zidovudine for preventing relapse, 415
  thrombocytopenia and HLA-B35, in drug users, 926
AIDS Commentary, *M. avium* infection and AIDS, 1326
Algaemia, protothecal, Hickman catheter-related, 930
Alveolar cells, and cytokines, interaction with *P. carinii*, in vitro, 611
Amoxicillin/clavulanate, for methicillin-resistant *S. aureus*, 514
Amoxicillin/clavulanic acid, for *M. leprae* infection, in mice, 1374
Amphotericin B, improved activity with anti-*C. neoformans* MAb, 1141
Ampicillin
  killing of *L. monocytogenes*, 574
  vs. TMP/SMZ, for pyelonephritis, 325
Anaerobic infection, due to *P. magnus*, pathogenesis, 1148
Anemia, severe, due to *P. falciparum*, 96
Animal model
  cryptosporidiosis, immunodeficient mice, 1297
  murine, fetal enterovirus infection, 1336
Antibiotics
  for gram-negative bacteremia, predictive index, 193
  for neutropenia and unexplained fever, 201, 202, 203
Antibody
  mono- and polyclonal, to GBS, 792
  monoclonal
    to CMV, safety and pharmacokinetics in BMT, 1344
    to murine coronavirus receptor, 879
  neutralizing, to hepatitis A virus, 634
Antibody to
  A. fumigatus proteins, immunoblot analysis, 1305
  B. pertussis, in humans, 135
  capsular polysaccharide of *S. aureus*, for diagnosis, 530
  core LPS determinants, 762, 769
  EBV, 53
  HCV, in posttransfusion patients, 1354
  hepatitis C virus, in chronic hepatitis B carriers, 400
  HIV, saliva vs. blood, 699
  HTLV-I, 47
  HTLV-I and -II, 41, 57
  IFN, frequency in patients treated with IFN, 882
  pertussis, 559
  RSV, 693
  streptococcal C5a peptidase, 109
  TNFα, in sepsis models, 83
Appendicitis, acute, due to *B. coli*, 1392
Arachidonic acid, metabolism, by peritoneal macrophages, 837
Arthritis, experimental bacterial, role of cytokines in induction, 1267
Aspergillosis, in CGD, recombinant human IFN-γ for, 908
Aspergillus fumigatus
  binding to human monocytes, inhibited by β1,4-glucosides, 1154
  damage by CGD neutrophils, 849
  invasive disease, serologic response to, 1305
Autoagglutination, phenotypes of pathogenic *Aeromonas*, 890
Autoimmunity, γδ T cells, and mycobacterial HSP, 156
Azithromycin, anticryptosporidial activity, in immunosuppressed rats, 1293
AZT (*See* Zidovudine)

β-lactams, for methicillin-resistant *S. aureus*, 1165, 1166
β-lysin, killing of *L. monocytogenes*, 574
β-microglobulin, spinal fluid levels, in HIV infection, 971
β1,4-glucosides, inhibition of *A. fumigatus* binding by monocytes, 1154
Bacteremia
  E. (Streptococcus) faecalis, gentamicin-resistant, streptomycin-susceptible, 1343
  gram-negative, predictive index for treatment, 193
  Salmonella, in AIDS, zidovudine for, 415
Baculovirus, expression of RSV protein, 477
Balantidium coli, acute appendicitis, 1392
Blastomyces dermatitidis
  dimorphism, 371
  molecular analysis, 1378
Bone marrow transplantation, immunoglobulins in CMV-infected recipients, 628
Bordetella pertussis
  envelope-associated proteins and adenyl cyclase toxin, human antibody response, 135
  immune response to infection and vaccination, 559
  modulation of infection by MAbs to pertussis toxin, 355
Borrelia burgdorferi
  cytotoxicity for rat glial cells, 1362
  epidemiology of infection, in Swiss orienteers, 305
  infection, inhibition by immune serum, 656
  infectivity
    in mice, 419
    and resistance to phagocytosis, 150
  isolation by needle aspiration, 895

Cachectin (*See* Tumor necrosis factor)
Campylobacter, diarrhea, group 2 aerotolerant species, 1062
Campylobacter coli, DNA, pulsed-field gel electrophoresis, 1068
Campylobacter jejuni, DNA, pulsed-field gel electrophoresis, 1068
Candida albicans, fibronectin receptor mediates adherence, 604
Candida krusei, infection, treatment failure with fluconazole, 420
Catheter-related infection, due to protothecal algaemia, 930
CD4–*Pseudomonas aeruginosa* exotoxin, recombinant protein, anti-HIV activity of, 703
Cefotaxime, and ceftriaxone, for Lyme borreliosis, 311
Ceftriaxone, and cefotaxime, for Lyme borreliosis, 311
Chlamydia pneumoniae
  infection, in Brooklyn, 757
  seroprevalence, in Japan, 417
Chlamydia trachomatis
  ocular infection, epidemiology, 752
  serovars Da, Ia, L2a, 403
  typing, by detection of RFLP in MOMP gene, 1103

The Journal of Infectious Diseases 1991;163:1415–1421
© 1991 by The University of Chicago. All rights reserved.
0022–1899/91/6306–0050$01.00

Cholera, vaccine, oral, evaluation of disease risk, in Bangladesh, 1235
Chronic granulomatous disease, aspergillosis in, recombinant human IFN-γ for, 908
Ciprofloxacin
development of resistance, in methicillin-resistant and -susceptible *S. aureus*, 1279
for pneumonia due to *S. pneumoniae*, in mouse model, 319
and rifampin, for *S. aureus* endocarditis, 204
Cirrhosis, and pneumonia, due to *S. pneumoniae*, 102
Clavulanate/amoxicillin, for methicillin-resistant *S. aureus*, 514
Cloxacillin, treatment of *S. aureus* endocarditis, tolerant strain, 640
Coccidioidomycosis, diagnosis of early infection, 671
Collaborative research, and world health, 946
Collagenase, production by *P. magnus*, 1148
Condylomata acuminata, infections with HPV, 393
Connective tissue diseases, association with pneumococcal soft-tissue infections, 897
Coronavirus, in vivo inhibition by MAb to receptor, 879
Cryptococcus neoformans gattii, environmental isolation, from California, 929
Cryptococcus neoformans
infection, amphotericin B and MAb for, 1114
killing by mononuclear cells, 1108
Cryptosporidium parvum
chronic infection, in immunodeficient mice, 1297
infection, azithromycin for, 1293
Cystitis, due to *E. coli*, urovirulence determinants, 773
Cytokines
and alveolar cells, interaction with *P. carinii*, in vitro, 611
in endotoxemia, augmentation by ibuprofen, 89
role in induction of experimental arthritis, 1267
Cytomegalovirus
ganciclovir-resistant
FIAU for, 1388
foscarnet for, 1348
glycoprotein B sequences, interstrain variation, 1229
human, nucleoside analogs, inhibitory effects of, 270
immunoglobulins in recurrent infection, 628
infection
ganciclovir resistance in, 716
in sexually active adolescents, 460
MAb to, safety and pharmacokinetics in BMT, 1344
murine
host genetic influences on fetal susceptibility, 276
primary maternal infection and fetal outcome, 276
pneumonia, profound hypogammaglobulinemia, 631
reactivation, localization in cervix, 921
Cytotoxin, *P. aeruginosa*, induction of vascular injury, in rabbit lungs, 362

Diaphragm use, *E. coli* urovirulence, 773
Diarrhea, due to
Campylobacter, in Thai children, 1062
E. coli
diffuse-adhering, in Mayan children, 507
ETEC, risk and ABO blood groups, 1243
rotavirus, prevention by vaccine, 483
Y. enterocolitica, pediatric, 660
Diarrhea, measles-associated, pathogenic agents and impact on growth, 495
2'-3'dideoxycytidine, and zidovudine, in murine induced immunodeficiency model, 869
Diethylcarbamazine, for filariasis due to *W. bancrofti*, 1157
Difluoromethylornithine, for PCP, 1121

Ehrlichiosis, human, serologic diagnosis, 564
Ehrlichia canis, serologic diagnosis of human ehrlichiosis, 564
ELISA
to detect coccidioidal antigens and antibodies, 671
to diagnose
pertussis, 1046
yersiniosis, 409
Encephalitis, due to
HSV, brain biopsy for diagnosis, 17
HSV-1, murine model, 720
Encephalitozoon hellem, from AIDS patients with keratoconjunctivitis, 617
Endocarditis, due to *S. aureus*,
diagnosis by antibody to capsular polysaccharide, 530
right-sided, treatment for, 204
treatment of tolerant strain, 640
Endotoxemia, augmented cytokines in endotoxemia, 89
Enteric infections, vaccines against, in developing countries, 503
Enterococci, enhanced killing by vancomycin, in rat model, 1358
Enterococcus (Streptococcus) faecalis
bacteremia, gentamicin-resistant, streptomycin-susceptible, 1343
evidence for clonal spread, 780
Enterovirus, murine, placental barrier to fetal infection, 1336
Enzyme immunoassay, peptide-based, to discriminate HTLV-I and -II, 41
EORTC report, therapy for fever in granulocytopenia, 951
Epidemiology
antibodies to human retroviruses, in IVDU, in East Coast cities, 1972–1976, 57
B. dermatitidis, molecular analysis, 1378
C. jejuni and *C. coli*, by pulsed-field gel electrophoresis, 1068
C. pneumoniae
infection, in Brooklyn, 757
seroprevalence, in Japan, 417
CMV, in sexually active adolescents, 460
diarrhea, due to
Campylobacter, in Thai children, 1062
diffuse-adhering *E. coli*, in Mayan children, 507
Y. enterocolitica, pediatric, 660
E. faecalis, evidence for clonal spread, 780
hepatitis A, foodborne, effect of microwaving food, 918
hepatitis A virus
genetic differentiation, 286
transmission in Thailand, 989
hepatitis B vaccination program, compliance of IVDU, 923
HIV, transmission via semen, 386
HTLV-I, vertical transmission, 204
HTLV-II
endemic, 435
infection in a cohort of IVDU, 252
loiasis, endemic and nonendemic, 1318
Lyme borreliosis
in at-risk population, 305
in South America, 681
malaria, therapy for, in Africa, 1207
measles, in Amish, 12
measles-associated diarrhea, in Peruvian children 495
molecular, *S. dysenteriae*, 406
nosocomial infection, legionnaires' disease, 607
ocular chlamydial infection, 752
parvovirus infection, occupational risk factors, 282
relapsing fever, in US Virgin Islands, 1391
RSV
age-related prevalence of antibody, 679

in Argentinian children, 1167
multicenter study, 687
pattern of epidemics, in Finland, 454
S. aureus, nosocomial transmission, after coronary artery bypass surgery, 117
S. pneumoniae, antimicrobial resistance
group 9 strains, 812
in Hungary, 542
in US, 1273
vaccine, against enteric infection, in developing countries, 503
Epstein-Barr virus
detection of *trans*-activator antibody, in HIV infection, 53
excretion from male genital tract, 1341
primary infection, in immunosuppressed patients, 1385
transformation-incompetent strain, 1008
Escherichia coli
antibiotic-treated, immunogenicity in mice, 122
cloning, expression of *S. aureus* genes, 1080
comparison between IgG1 and IgM MAbs, 346
conjugate vaccine against, safety and immunogenicity, 1040
diarrhea, in Mayan children, 507
EPEC, inhibition of adherence, by breast milk, 1241
ETEC, diarrhea and ABO blood groups, 1243
J5, immunization of humans, 769
urovirulence determinants, causing cystitis, 773
Ethanol, effect on
M. avium infection, 1286
neutrophil adhesion, 591
pathogenesis of pneumococcal pneumonia, 799

Fermentation, history of, 937
FIAU, antiviral activity, against ganciclovir-resistant CMV, 1388
Fibronectin, receptor, mediates *C. albicans* adherence, 604
Filariasis, due to *W. bancrofti*, diethylcarbamazine for, 1157
Flucytosine, for cryptococcal meningitis, artifactual elevation of serum creatinine, 421
Fluoroquinolones, *S. aureus* resistance, 1080
Foscarnet
combined with AZT, for HIV infection, 1219
for ganciclovir-resistant CMV, in AIDS, 1348
Fungemia, due to *C. krusei*, treatment failure with fluconazole, 420
Fungi, dimorphic, phase transition and pathogenesis, 371

Ganciclovir, resistance in CMV infection, 716
Glial cells, cytotoxicity of *B. burgdorferi* for, 1326
Globulin, hyperimmune, against *P. aeruginosa* and *Klebsiella*, 1055
Gonorrhea, immunization against, with pilus vaccine, 128
Granuloctye colony-stimulating factor, enhancement of phagocytic and bactericidal neutrophil activity, 579
Granulocyte-macrophage colony-stimulating factor, recombinant murine, enhances resistance to infection, 584
Granulocytopenia, in cancer, vancomycin therapy, 951
Group A streptococci, C5a peptidase, 109
Group B streptococcal infection, IgG for, 1141
Group B streptococci
C protein–associated antigens, association with neonatal sepsis, 786
comparison of IgG1 and IgM MAbs, 346
human monoclonal and hyperimmune polyclonal antibody to, 792

Haemophilus influenzae
invasive infection, and immunoglobulin G2m(n) allotype, 637
nontypable, interaction with respiratory mucosa, 549
resistance to clearance mechanisms, 1073
suppurative arthritis, role of cytokines in induction of, 1267
type b, interactions with macrophages, and virulence, 1366
Hansen's disease, cell-mediated immunity and lymphokines, 1195
Health care workers, prevaccination serologic screening, for measles, 876
Heat-shock proteins, mycobacterial, 156
HeLa cells, CD4-positive, for quantification of HIV, 64
Hepatic disease, and HIV infection, 866
Hepatitis A
foodborne, effect of microwaving food, 918
infection, secretory immunity in, 7
virus
assay for neutralizing antibodies, 634
epidemiologic patterns, genetic variation, 286
live attenuated vaccine, safety and immunogenicity of, 735
transmission, in Thailand, 989
Hepatitis B virus
chronic infection, influence of HIV infection, 1138
detection
by PCR, 397
in PBMC by PCR, 996
infection, in homosexual men, relation to prior HIV infection, 454
vaccination, among drug addicts, 923
vaccine, dosing schedule, 1384
Hepatitis C virus
antibodies, in posttransfusion hepatitis patients, 1354
antibody prevalence, in HIV-infected patients, 414
in chronic hepatitis B carriers, 400
detection of, in non-A, non-B hepatitis, 923
genomic heterogeneity, 1383
Hepatitis D virus, infection, effect of HIV infection on, 1351
Hepatitis
due to HSV, 1001
interferon-α for, 882
Hermitia illucens, intestinal myiasis, 1170
Herpes simplex labialis
acyclovir for, 728
encephalitis, brain biopsy for diagnosis, 17
UV-radiation-induced, acyclovir for, 728
Herpes simplex virus
infection after transplant, 1001
type 1
encephalitis, murine model, 720
prior infection prevents HSV-2 infection, 679
type 2, latency-associated transcription, 23
zosteriform, treatment with MAbs, 263
Herpes zoster, T cell responses, 873
HLA-B35, and thrombocytopenia, in IVDU with AIDS, 926
Human herpesvirus 6
antiviral susceptibility, in vitro, 1382
DNA, detection in PBMC from kidney transplant patients, 925
electrophoretic analysis of polypeptides, 29
Human immunodeficiency virus
anti-HIV activity of CD4–*P. aeruginosa* exotoxin, 703
antiidiotypic immunization, 389
heterosexual transmission, cofactors, 233
infection
AZT for, in pregnant mice, 1212
and bacteremic meningococcal pneumonia, 1390
combined AZT and foscarnet therapy for, 1219
detection of EBV antibody in, 53
effect on HDV infection, 1351
and hepatic disease, 866
immune system activation, 971
immunology and virology, 959

influence on development of chronic HBV infection, 1138
polyclonal B cell activation, 240
prevalence of HCV antibody, 414
and syphilis, 1201
treatment during pregnancy, 226
zidovudine and IFNα for, 710
infectivity assay, 64
inhibition with BI-RG-587, 966
pathology and expression in placenta, 1134
postexposure AZT prophylaxis against, 625
prevalence testing, using saliva or blood, 699
reactivity, indeterminate Western blots, 247
recovery from semen, 386
RNA, detection in serum by PCR, 862
type 1
effect on HBV infection, 454
enhanced replication in macrophages by TNFα, 78
infection in chimpanzees, 441
vaccine, genetically engineered, 219
vaccine, lymphoproliferative response, 448
Human T cell leukemia virus
type I
antibody, cross-reactivity with *P. falciparum*, 257
tax gene antibody in T cell leukemia, 47
vertical transmission, 204
Western blot and RIA, to detect antibody to, 1387
type II
in cohort of IVDU, 252
incidence of HCL, mycosis fungoides, and CLL, 435
types I and II
antibodies among IVDU, 57
serologic discrimination by EIA, 41
Hydrogen peroxide, interaction with *B. dermatitidis*, 371
Hydroxynapthoquinone, for pneumonitis due to *P. carinii*, 843
Hypergammaglobulinemia
due to CMV pneumonia, 631
evolution in HIV infection, 240

Ibuprofen, and cytokines, 89
IDSA
announcement, preliminary 1991 IDSA program, 1172, 1396
postdoctoral fellowship recruitment, 207, 423
presentation
antimalarial therapy in Africa, 1207
Hansen's disease, 1195
IL-1 and TNF, for septic shock syndrome, 1177
new aspects of antimicrobial resistance, 1185
sepsis, riddle of, 937
IgG, human
hyperimmune, for GBS infection, 1141
relative activity to IgM, 346
IgM, human, class-switched to IgG1, 346
Immunity
cell-mediated, in Hansen's disease, 1195
mucosal, induced by polio vaccines, 1
passive, role in bovine RSV infection, 470
secretory, in hepatitis A infection, 7
Immunization, antiidiotypic, against HIV, 389
Immunodeficiency, induced, murine model, 869
Immunoglobulin, G2m(n) allotype, and invasive *H. influenzae* disease, 637
Immunoglobulins, in recurrent CMV infection, 628
Indomethacin, role in pathophysiology of experimental meningitis, 647
Infection control, legionnaires' disease, 413
Influenza, vaccine, 1023
Influenza A virus, protection with attenuated and inactivated vaccines, 300
Influenza B, live attenuated cold-adapted vaccine, safety and immunogenicity of, 740
Interferon-α
neutralizing antibodies to, 882
with zidovudine, for HIV infection, 710
Interferon-γ
for aspergillosis, in CGD, 908
augmenting CGD neutrophil function, 849
elevated, in melioidosis, 1145
endogenous, to activate macrophages, against *T. cruzi*, 912
for *P. vinckei* malaria, 1161
Interleukin-1
inhibitor, activity induced by RSV and influenza virus, 71
and TNF, for septic shock syndrome, 1177
Interleukin-2 receptors, elevated, in melioidosis, 1145
Intraabdominal infections, effects of antigen exposure, 664
Intravenous drug users, detection of antibodies to retroviruses, 57
Ivermectin, for *O. volvulus* infection, treatment regimens, 376, 381
Ixodes dammini, duration of feeding by adult females, 895

Kawasaki disease, and infectious mononucleosis, CD8 T cells and NK cells, 416
Keratoconjunctivitis, due to a new microsporidium, in AIDS, 617
Klebsiella, hyperimmune globulin against, 1055

Legionella pneumophila, control, treatment of potable water, 413
Legionnaires' disease
infection control, 413
nosocomial, and nebulizer use, 667
Leishmania donovani, response to experimental chemotherapy, 622
Leishmaniasis, human visceral, TNF in, 853
Leprosy, urinary phenolic glycolipid, in diagnosis, 653
Lipopolysaccharide
antibodies to core determinants, absence of cross-reactivity, 762
role of serum in binding to IgG, 1256
Lipoproteins, high-density, complexes with LPS, 762
Listeria monocytogenes
cross-infection, confirmed by isoenzyme typing, 927
serum killing, 574
Listeriosis, neonatal, due to cross-infection, 927
Loiasis, immunologic basis for clinical manifestations, 1318
Lower repiratory tract infection, in children, TNFα levels in, 1029
Lyme disease
duration of attachment of adult ticks, 895
genetic resistance, 419
microcapsule agglutination test, for serologic studies, 682
mouse model, 419
prevalence and incidence, in at-risk population, 305
protection against, by immune serum, 656
in South America, 681
Lyme neuroborreliosis, comparison of ceftriaxone and cefotaxime for, 311
Lymphadenopathy, evolution in HIV infection, 240
Lymphocyte
B cell activation in HIV infection, 240
proliferative response, to HIV-1 vaccine, 448
Lymphopenia, in HIV-infected chimpanzees, 441
Lysozyme, killing of *L. monocytogenes*, 574

Macaques, SIV infection, levels of provirus in tissue, 976
Macrophage
effects of typhus rickettsiae, 568
interaction with *B. dermatitidis*, 371

peritoneal, response to CAPD bacterial isolates, 837
role in cerebral malaria, 1394
Malaria
and HTLV-I reactivity, 257
inactivation of parasites by photoirradiation, 1312
P. vinckei, IFN-γ enhances chemotherapy for, 1161
role of macrophage in, 1394
therapy for, in Africa, 1207
and TNF, 96
Measles
risk factor for diarrhea, etiologic study, 495
serologic screening, for health care workers, 876
severity of, in Amish, 12
Mediastinitis, with methicillin-resistant *S. aureus*, after coronary artery bypass surgery, 117
Melioidosis, immune cell activation, 1145
Meningitis
bacterial, role of PAF, 1164, 1168
due to
Acanthamoeba, rifampicin for, 916
M. tuberculosis, antigen detection for diagnosis, 650
S. pneumoniae strains, 806
experimental, effect of indomethacin on pathophysiology, 647
TNFα in spinal fluid in, 886
Microsporidiosis, due to *E. hellem* (n. sp.), 617
Molecular hybridization, HSV transcription, 23
Monoclonal antibodies, human IgG1 and IgM functional activities, 346
Monoclonal antibody
anti-*C. neoformans*, improved activity of amphotericin B, 1114
to pertussis toxin, role in immunity, 355
for zosteriform protection, due to HSV, 263
Monocyte, binding to *A. fumigatus* conidia, inhibited by β1,4-glucosides, 1154
Mononuclear cells, killing of *C. neoformans* by, 1108
Mononucleosis, and Kawasaki disease, CD8 T cells and NK cells, 416
Mycobacterium avium, infection
and AIDS, 1326
effect of ethanol, 1286
Mycobacterium fortuitum
clinical disease, drug susceptibility, and biochemical patterns, 598
soft-tissue infection, associated with electromyography, 1150
Mycobacterium leprae
amoxicillin/clavulanic acid for, in mice, 1374
phenolic glycolipid 1, role in diagnosis and management, 653
Mycobacterium tuberculosis
detection of antigen 5, diagnostic role in meningitis, 650
neutrophil killing, 919
strain differentiation, by nonradioactive Southern blot hybridization, 904
synthesis and seroreactivity of a neoantigen, 161
Myiasis
intestinal, due to fleshflies and horseflies, 1170
ocular, due to *O. tarandii*, 931

Neisseria gonorrhoeae, pilus vaccine, 128
Neisseria meningitidis, pneumonia, and HIV infection, 1390
Neonatal infection, due to GBS, IgG for, 1141
Neurosyphilis, experimental model, 825
Neutropenia, and unexplained fever, antibiotics for, 201, 202, 203
Neutrophil
adhesion, impaired by ethanol, 591
in CGD, function augmented by IFN-γ, 849
chemorepulsion of trichomonads, 176
enhanced phagocytic and bactericidal activity, by G-CSF, 579
and free radicals, a spin-trapping study, 819
human, antimicrobial activity of cytoplasmic calcium-binding protein, 187
response to *E. coli*, augmented by TNFα, 1033
Non-A, non-B hepatitis, detection of serum hepatitis C virus RNA in, 925
Norfloxacin, energy-dependent drug efflux, 1080
Nosocomial infection, legionnaires' disease, 413, 667
Nucleoside analogs, inhibitory effects on CMV, 270

Ocular infection
due to *C. trachomatis*, epidemiology, 752
ophthalmomyiasis interna posterior, due to larval reindeer warble fly, 931
Oedomagena tarandii, ophthalmomyiasis interna posterior, 931
Ofloxacin, for pneumonia due to *S. pneumoniae*, in mouse model, 319
Onchocerca volvulus infection
humoral host defense, 1128
ivermectin for, community-based treatment regimens, 376, 381
Ophthalmomyiasis interna posterior, due to larval reindeer warble fly, 931
Oral contraceptives, and HIV-1 infection, 233

Papillomaviruses, human, in condylomata acuminata, 393
Parasarcophaga crassipalpis, intestinal myiasis, 1170
Parasites, malarial, inactivation by photoirradiation, 1312
Parvovirus infection, occupational risk factors, in pregnancy, 282
Pathophysiology, meningitis due to *S. pneumoniae*, 806
Pentamidine, iv, pharmacokinetics, in normal or impaired renal function, 169
Peptostreptococcus magnus, collagenase production and anaerobic pathogenesis, 1148
Peripheral blood mononuclear cells, killing of *C. neoformans* by, 1108
Peritonitis, related to CAPD, response of peritoneal macrophages, 837
Pertussis
laboratory diagnosis, by serology and nasopharyngeal culture, 1046
toxin, MAb against, 355
Phagocytosis, by monocytes and free radicals, 819
Pharmacokinetics
pentamidine, 169
vancomycin, by CSF reservoir, 197
Phenolic glycolipid 1, of *M. leprae*, role in diagnosis and management, 653
Phenotypic conversion, of *H. influenzae*, by host factors, 1073
Photoirradiation, merocyanine 540-sensitized, for purging malarially infected RBC, 1312
Placenta, pathology and expression of HIV in, 1134
Plasmodium falciparum
and HTLV-I reactivity, 257
infection, in Africa, 1207
Plasmodium vinckei, malaria, IFN-γ enhances chemotherapy for, 1161
Platelet-activating factor, and bacterial meningitis, 1164, 1168
Pneumocystis carinii
interaction with cytokines and alveolar cells, 611
pneumonia, difluoromethylornithine for, 1121
pneumonitis, hydroxynapthoquinone for, 843
taxonomic status, 675
Pneumonia
bacteremic meningococcal, and HIV infection, 1390
due to
CMV, profound hypogammaglobulinemia, 631
P. carinii, difluoromethylornithine for, 1121
S. pneumoniae
detection of capsular polysaccharide for diagnosis, 1094
in cirrhosis, 102
quinolones for, 319

etiology, diagnostic criteria, 1087
pneumococcal, chronically intoxicated rat model, 799
Pneumonitis, due to *P. carinii*, in AIDS, hydroxynapthoquinone for, 843
Polio, vaccines, mucosal immunity induced by, 1
Polymerase chain reaction
to amplify MOMP gene of *C. trachomatis*, 1103
to detect
EBV, in male genital tract excretion, 1341
HBV DNA, in HBsAg-negative plasma, 397
HBV in PBMC, 996
HCV RNA, 923
HIV RNA in serum, 862
HPV, in condylomata, 393
HTLV-I, 204
T. gondii, 180
VZV, 1016
Polymorphonuclear leukocyte, response to *E. coli*, augmented by TNFα, 1033
Pregnancy
parvovirus B19 infection in, occupational risk, 282
use of zidovudine in, 226
Prototheca wickerhamii, catheter-related infection, 930
Proviral DNA, SIV, levels in tissue, 976
Pseudomonas aeruginosa
cytotoxin, induction of vascular injury, in rabbit lungs, 362
hyperimmune globulin against, 1055
regulation of virulence, in vivo, 143
Pseudomonas pseudomallei, melioidosis, immune cell activation, 1145
Pulsed-field gel electrophoresis, for epidemiologic study of *C. jejuni* and *C. coli*, 1068
Pyelonephritis, ampicillin vs. TMP/SMZ for, 325

Quinolones, for pneumonia due to *S. pneumoniae*, 319

Radioimmunoprecipitation assay, and Western blot, to confirm HTLV-I antibody detection, 1387
Relapsing fever, epidemiology, in US Virgin Islands, 1391
Resistance
antimicrobial
S. pneumoniae, 1273
and therapy, 1185
ciprofloxacin, in *S. aureus*, 1279
ganciclovir, in CMV infection, 716, 1388
methicillin
β-lactams for, 1165, 1166
in *S. aureus*, mechanisms of, 514
S. aureus
ciprofloxacin, 1279
foreign body infection, 1369
methicillin, β-lactams for, 1165, 1166
methicillin, mechanisms of, 514
Respiratory syncytial virus
age-related prevalence of antibody, 679
group A, antigenic and genomic diversity, 858
induction of IL-1 inhibitor activity, 71
infection
in Argentina, 1167
bovine, role of passive immunity, 470
pattern of epidemics, in Finland, 464
reinfection, immunity and frequency, 693
strains, multicenter study, 687
vaccine, enhanced pathology in cotton rat, 477
Restriction endonuclease analysis, adenovirus type 31, 293
Restriction fragment length polymorphisms, to differentiate *M. tuberculosis* strains, 904
Retrovirus, transmission, in nonhuman primates, by blood transfusion, 1223
Reverse transcriptase, HIV, inhibition with BI-RG-587, 966
RH blood group, and recurrent UTI, 681
Ribonuclease protection, analysis of group A RSV, 858
Ribonucleic acid
HIV, detection by PCR, 862
polyadenylated, detection in PBMC by PCR, 996
Rickettsia prowazekii, effects on macrophage autacoid secretion, 568
Rifampicin
and ciprofloxacin, for *S. aureus* endocarditis, 204
for meningitis, due to *Acanthamoeba*, 916
Rotavirus, vaccine, safety and efficacy, 483

Salmonella, bacteremia, in AIDS, zidovudine for prevention of, 415
Salmonella typhi Ty21a, human humoral immune response to, 336
Sarcophaga peregrina, intestinal myiasis, 1170
Scrapie, prion proteins, membrane interaction, 488
Sepsis
ancient riddle of, 937
models, role of TNFα in, 83
neonatal, association with GBS C protein-associated antigens, 786
Septic shock syndrome, TNF and IL-1 for, 1177
Serum creatinine, in patients receiving flucytosine for cryptococcal meningitis, 421
Sexually transmitted disease
CMV, in adolescents, 460
and HIV-1, 233
Shigella dysenteriae type 1, molecular epidemiology, 406
Simian immunodeficiency virus
infection, of macaques, 976
transmission, 1223
Slime, from coagulase-negative staphylococci, composition of, 534
Soft-tissue infection, due to
M. fortuitum, associated with electromyography, 1150
S. pneumoniae, association with connective tissue diseases, 897
Staphylococci, coagulase-negative, isolation and composition of slime, 534
Staphylococcus aureus
antimicrobial resistance, foreign body infection, 1369
endocarditis
diagnosis, by antibody to capsular polysaccharide, 530
experimental, ciprofloxacin resistance, 1080
rifampin and ciprofloxacin for, 204
role of tolerance in treatment, 640
methicillin-resistant
β-lactam resistance mechanisms in, 514
β-lactams for, 1165, 1166
and -susceptible, ciprofloxacin resistance in, 1279
nosocomial infection, after coronary artery bypass surgery, 117
toxic shock syndrome, 678
toxic shock syndrome toxin 1 synthetic peptide, mitogenic effect of, 524
Statistical model, for diagnosis of HSV encephalitis, 17
Streptococcus pneumoniae
antibiotic-resistant
in Hungary, 542
in US, 1273
group 9, protein and capsular types, epidemiology, 812
infection, chronically intoxicated rat model, 799
meningitis, pathophysiology of, 806
pneumonia

in cirrhosis, 102
diagnosis, 1087, 1094
quinolones for, 319
serotypes and vaccine, 644
soft-tissue infection, 897
Sudden infant death syndrome, role of bacteria and viruses, 35
Syphilis
and HIV infection, 1201
neurosyphilis, penicillin, and AIDS, 1201
pathogen-specific humoral response in, animal models, 830

T cell
γδ, mycobacterial HSP and autoimmunity, 156
helper function, in HIV infection, 971
leukemia, HTLV-I *tax* gene antibody, 47
Temafloxacin, for pneumonia due to *S. pneumoniae*, in mouse model, 319
Thrombocytopenia
in HIV-infected chimpanzees, 441
and HLA-B35, in IVDU with AIDS, 926
Toxic shock syndrome
and staphylococcal infection, 678
toxin 1 synthetic peptide, mitogenic effect of, 524
Toxins, bacterial, exacerbation by influenza virus, in SIDS, 35
Toxoplasma gondii, diagnosis, by PCR and cDNA, 180
Trachoma, epidemiology, 752
Treponema pallidum
CNS invasion, 825
infection, specific humoral response, 830
meningitis model, 825
Trichomonas vaginalis, chemorepulsion by neutrophil products, 176
Trimethoprim-sulfamethoxazole, vs. ampicillin, for pyelonephritis, 325
Trypanosoma cruzi, infection, host defense, 912
Tumor necrosis factor
in human visceral leishmaniasis, 853
and IL-1, for septic shock syndrome, 1177
and malaria, 96
Tumor necrosis factor-α
bioactive and inactive forms, in spinal fluid, 886
cachectin, enhancement of HIV-1 replication, in macrophages, 78
concentrations in children with respiratory tract infection, 1029
E. coli and neutrophil activation, 1033
role, in sepsis models, 83
Typhoid fever, Ty21a vaccine, 901

Urinary tract infection
linked host response parameters, 331
recurrent, and Rh blood group, 681
single-dose treatment, metaanalysis of, 928

Vaccine
against
enteric infection, public health prospects in developing countries, 503
hepatitis A, live attenuated, 735
hepatitis B
among drug addicts, 923
dosing schedule, 1384
HIV, safety and efficacy, 219
HIV-1, lymphoproliferative response, 448
influenza A, attenuated vs. inactivated, 300
rotavirus, safety and efficacy, 483
RSV, enhanced pathology in cotton rat, 477
conjugate, against *E. coli*, safety and immunogenicity, 1040
humoral response to live oral typhoid, 336
influenza, attenuated, 1023
influenza B, safety and immunogenicity of, in infants and children, 740
pneumococcal, and respiratory isolates, 644
oral cholera, efficacy, in Bangladesh, 1235
polio, enhanced-potency inactivated and oral, 1
Ty21a, with Vi antigen, immune response, 901
Vancomycin
for CNS reservoir-associated infection, pharmacokinetics, 197
empirical antibiotic therapy, in granulocytopenia, 951
enhanced killing of enterococci by, in rat model, 1358
Varicella, animal model, hairless guinea pigs, 746
Varicella-zoster virus
immunity after herpes zoster, 873
infection, in guinea pigs, 746
PCR for detection and investigation, 1016
Vi antigen, of *S. typhi*, expressed on Ty21a, 901
Vibrio cholerae, infection, serologic immunity, 1235
Virulence
H. influenzae type b, relation to survival in macrophages, 1366
regulation in *P. aeruginosa*, associated with genetic rearrangement, 143

Western blot
for HIV, indeterminate reactions, 247
HTLV indeterminate reactivity, 257
and RIA, to confirm HTLV-I antibody detection, 1387
Whipple's disease, bone marrow involvement, 1169
World health, and collaborative research, 946
Wucheria bancrofti, filariasis, diethylcarbamazine for, 1157

Yersinia enterocolitica, diarrhea, in children, 660
Yersinia, serum antibody to, ELISA for, 409

Zidovudine
combined with foscarnet, for HIV infection, 1219
and 2'-3'dideoxycytidine, in murine induced immunodeficiency model, 869
efficacy of prophylaxis for *Salmonella* bacteremia, in AIDS, 415
embryonic toxicity, in mice, 1212
with IFNα, for HIV infection, 710
pharmacokinetics, in pregnancy, 226
postexposure prophylaxis against HIV-1, in mice, 625
Zosteriform, due to HSV, treatment with MAbs, 263